Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 43

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Transitional cell carcinoma+1

Not recruiting

Study of Futibatinib and Pembrolizumab for Patients with Advanced or Metastatic Bladder, Urethra, or Pelvis Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Futibatinib
  • Sponsor:Taiho Oncology Inc.

Phenylketonuria

Not recruiting

Study to Evaluate mRNA-3210 for Safety and Tolerability in Patients with Phenylketonuria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Moderna Therapeutics Inc.

Hepatocellular carcinoma+14

Not recruiting

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Incb099280
  • Sponsor:Incyte Corp.

Glomerulonephritis membranous

Not recruiting

Study of Zanubrutinib and Tacrolimus for Patients with Primary Membranous Nephropathy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:BeOne Medicines AG

Lupus nephritis

Not recruiting

Study on Zetomipzomib for Patients with Active Lupus Nephritis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Kezar Life Sciences Inc.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Switching from Anti-C5 Antibody Treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan for Patients with Advanced Kidney Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Hyperparathyroidism secondary

Not recruiting

Study on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End Stage Kidney Disease on Hemodialysis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Upacicalcet Sodium Hydrate
  • Sponsor:Pathalys Pharma Inc.

Hyperparathyroidism secondary

Not recruiting

Study on the Effectiveness and Safety of PLS240 for Treating Secondary Hyperparathyroidism in Patients with End-Stage Kidney Disease on Hemodialysis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Upacicalcet Sodium Hydrate
  • Sponsor:Pathalys Pharma Inc.

Bladder transitional cell carcinoma+2

Not recruiting

Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Seagen Inc.

Complications of transplanted kidney+1

Not recruiting

Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.